GIVE MOVE
Genotype-Informed Versus Empiric Management Of VirEmia: An Open-Label Randomised Clinical Trial in Children and Adolescents living with HIV.
Towards optimised care for children and adolescents living with HIV
The Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE) randomised clinical trial assesses the clinical impact and cost-effectiveness of genotypic resistance testing of HIV to inform clinical management in HIV-positive children and adolescents whose treatment is failing to control the virus. Though routine in high-income countries, this key diagnostic tool is not available in many settings where it is most needed.
Assessing the clinical impact of HIV-1 genotypic resistance testing…
GIVE MOVE will assess the influence of genotypic resistance testing on clinical decision making and its impact on the health of children and adolescents with unsuppressed HIV-1.
…and if clinically relevant, assessing the cost and cost-effectiveness of HIV-1 genotypic resistance testing.
The cost and cost-effectiveness analysis, in combination with lessons learned with respect to feasibility, are intended to guide implementation of HIV-1 resistance testing in countries or settings were access is currently limited.